Abstract:Background: Treatment with KRASG12C inhibitors results in an objective response in only small fraction of patients with KRASG12C mutant colorectal cancer (CRC) (7.1% and 22% objective response rates (ORR) in two prospective trials), in contrast to lung cancer where the ORR exceeds 35%. We hypothesize that co-mutation of other oncogenes and/or transcriptomic factors may contribute to the resistance of KRASG12C CRC to KRAS inhibitors. Methods: Mutation profiles of CRC patients were obtained from the AACR Project-GENIE v14 CRC cohort (N = 9441). The impact of KRAS knockout in 59 CRC cell lines was queried from the DepMap database. KRASG12C mutant CRC cell lines SW837 and SW1463 were treated with Sotorasib (KRASG12C inhibitor), Vismodegib and Taladegib (Hedgehog inhibitors), and cell viability was measured up to 96 hours after treatment. Results: In the AACR Project-GENIE CRC (N = 9441) cohort, KRASG12C tumors (2.6%, 245/9441) were significantly co-mutated with PIK3CAmut (19.2%, 47/245; Odds ratio = 1.7 (95% CI: 1.2 - 2.4), Chi-Square test, p-value = 0.002). Dependence on KRAS in CRISPR knockout viability assays was higher in KRASmut vs. wildtype CRC cell lines (median CERES score -1.3 vs -0.5, p-value < 0.001). Interestingly, KRASmut cell lines with PIK3CA co-mutation (n=10) were more resistant to KRAS knockout than PIK3CAwt cells (n=22) (median -1.0 vs -1.4, p-value = 0.03). The SW837 and SW1463 cell lines initially displayed high sensitivity to Sotorasib (IC50: 0.92 μM and 0.90 μM). However, overexpression of PIK3CAE545K mutant induced resistance to the same treatment (IC50: 5.18 μM and 6.45 μM). Furthermore, gene set enrichment analysis (GSEA) showed that Hedgehog signaling was significantly enriched in KRAS knockout resistant KRASmut CRC cell lines. SW837 cell line treated with Sotorasib (S) and a fixed dosage of 25 μM of Vismodegib (V) or Taladegib (T) showed higher sensitivities in combination treatment assays (IC50 decreased: ~11 folds in S+V vs S; and ~15 folds in S+T vs S) as compared to Sotorasib (S) treatment alone. Similar results were seen for the SW1463 cell line (IC50 decreased: ~18 folds in S+V vs S; and ~15 folds in S+T vs S). Conclusion: Resistance in CRC to KRASG12C inhibitors may be attributed to activated PIK3CA mutations and the Hedgehog signaling pathway. The future study will focus on detailed investigations involving comprehensive transcriptome and exome profiles in tumors and PDX models treated with anti-KRAS drugs in monotherapy and combination therapy. Citation Format: Saikat Chowdhury, Jibran Ahmed, Valsala Haridas, David S. Hong, Scott Kopetz, John Paul Shen. Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1250.

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer

IDDF2024-ABS-0231 Targeting the Mevalonate Pathway Boosts Anti-Egfr Efficacy in Colorectal Cancer with KRAS Mutation

AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation.

Repotrectinib Increases KRAS-G12C Inhibitor Effectiveness Via Simultaneous Inhibition of SRC, FAK, and JAK2

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Feedback Activation of EGFR/wild-type RAS Signaling Axis Limits KRASG12D Inhibitor Efficacy in KRASG12D-mutated Colorectal Cancer

Targeting the PI3K signaling pathway in KRAS mutant colon cancer

Combine MEK Inhibition with PI3K/mTOR Inhibition Exert Inhibitory Tumor Growth Effect on KRAS and PIK3CA Mutation CRC Xenografts Due to Reduced Expression of VEGF and Matrix Metallopeptidase-9

Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways

Abstract 1250: Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Positive Feedback Between Oncogenic KRAS and HIF-1α Confers Drug Resistance in Colorectal Cancer.

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer: A Meta-Analysis

Dynamic Alterations of Genome and Transcriptome in KRAS G13D Mutant CRC PDX Model Treated with Cetuximab.

Acetyl-CoA Carboxylase Rewires Cancer Metabolism to Allow Cancer Cells to Survive Inhibition of the Warburg Effect by Cetuximab.

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation

KRAS Status and Resistance to Epidermal Growth Factor Receptor Tyrosine‐kinase Inhibitor Treatment in Patients with Metastatic Colorectal Cancer: a Meta‐analysis

Abstract 1946: Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations